Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luís M. Ruilope, Rajiv Agarwal, Stefan D. Anker, et al.
American Journal of Nephrology (2019) Vol. 50, Iss. 5, pp. 345-356
Open Access | Times Cited: 185

Showing 1-25 of 185 citing articles:

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris, Rajiv Agarwal, Stefan D. Anker, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 23, pp. 2219-2229
Open Access | Times Cited: 1749
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 12, pp. 1874-2071
Open Access | Times Cited: 1507
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, et al.
European Heart Journal (2021) Vol. 43, Iss. 6, pp. 474-484
Open Access | Times Cited: 670
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt, Jingmei Li, Rajiv Agarwal, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24, pp. 2252-2263
Open Access | Times Cited: 446
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal, Peter Kolkhof, George L. Bakris, et al.
European Heart Journal (2020) Vol. 42, Iss. 2, pp. 152-161
Open Access | Times Cited: 387
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Kunihiro Matsushita, Shoshana H. Ballew, Angela Yee‐Moon Wang, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 11, pp. 696-707
Closed Access | Times Cited: 326
Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
Rodica Pop‐Busui, James L. Januzzi, Dennis Bruemmer, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1670-1690
Open Access | Times Cited: 225
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, et al.
Circulation (2020) Vol. 143, Iss. 6, pp. 540-552
Open Access | Times Cited: 223
Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, et al.
Circulation (2021) Vol. 145, Iss. 6, pp. 437-447
Open Access | Times Cited: 166
Treatment of Diabetic Kidney Disease: Current and Future
Tomotaka Yamazaki, Imari Mimura, Tetsuhiro Tanaka, et al.
Diabetes & Metabolism Journal (2021) Vol. 45, Iss. 1, pp. 11-26
Open Access | Times Cited: 164
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects
Jonatan Barrera‐Chimal, Ixchel Lima‐Posada, George L. Bakris, et al.
Nature Reviews Nephrology (2021) Vol. 18, Iss. 1, pp. 56-70
Closed Access | Times Cited: 153
Signaling Pathways Involved in Diabetic Renal Fibrosis
Yuqing Zhang, De Jin, Xiaomin Kang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 140
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal, et al.
Kidney International Reports (2021) Vol. 7, Iss. 1, pp. 36-45
Open Access | Times Cited: 108
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Ulrich Kintscher, George L. Bakris, Peter Kolkhof
British Journal of Pharmacology (2021) Vol. 179, Iss. 13, pp. 3220-3234
Open Access | Times Cited: 108
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
Muthiah Vaduganathan, Gerasimos Filippatos, Brian Claggett, et al.
Nature Medicine (2024) Vol. 30, Iss. 12, pp. 3758-3764
Open Access | Times Cited: 27
Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets
Jonatan Barrera‐Chimal, Frédéric Jaisser
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S1, pp. 16-31
Open Access | Times Cited: 129
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
Edmund Y. M. Chung, Marinella Ruospo, Patrizia Natale, et al.
Cochrane library (2020) Vol. 2020, Iss. 10
Open Access | Times Cited: 111
Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease
Sijie Chen, Lin‐Li Lv, Bi‐Cheng Liu, et al.
Cell Proliferation (2020) Vol. 53, Iss. 3
Open Access | Times Cited: 103
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
Beatriz Fernández‐Fernández, Pantelis Sarafidis, Mehmet Kanbay, et al.
Clinical Kidney Journal (2020) Vol. 13, Iss. 5, pp. 728-733
Open Access | Times Cited: 90
Bariatric Surgery and Long-term Survival in Patients With Obesity and End-stage Kidney Disease
Kyle H. Sheetz, Laura Gerhardinger, Justin B. Dimick, et al.
JAMA Surgery (2020) Vol. 155, Iss. 7, pp. 581-581
Open Access | Times Cited: 81
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
Rajiv Agarwal, Stefan D. Anker, George L. Bakris, et al.
Nephrology Dialysis Transplantation (2020) Vol. 37, Iss. 6, pp. 1014-1023
Open Access | Times Cited: 75
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials
Ajay Chaudhuri, Husam Ghanim, Pradeep Arora
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 365-376
Open Access | Times Cited: 73
Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia
Guido Gembillo, Ylenia Ingrasciotta, Salvatore Crisafulli, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4824-4824
Open Access | Times Cited: 60
New progress in drugs treatment of diabetic kidney disease
Junmin Wang, Hongjiao Xiang, Yifei Lü, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 141, pp. 111918-111918
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top